Research location

Waterbury

Connecticut, United States

Published trials371

Site observations374

Linked trials published371

Page1 / 8

Research activity in Waterbury

Connecticut, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 371 trials and 374 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Waterbury

371 linked trials · page 1 of 8

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · 2026-09-16 · 1 site observation

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 2026-07-23 · 1 site observation

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · 2026-07-17 · 1 site observation

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307 · 2026-04-20 · 1 site observation

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 · 2026-04-13 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · 2026-02-06 · 1 site observation

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyNCT06769126 · 2025-11-06 · 1 site observation

A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionNCT07142356 · 2025-10-31 · 1 site observation

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)NCT06116682 · 2024-11-19 · 1 site observation

The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyNCT06377852 · 2024-10-29 · 1 site observation

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast CancerNCT06551116 · 2024-10-10 · 1 site observation

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08 · 1 site observation

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationNCT05806515 · 2024-03-01 · 1 site observation

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation

ATEMPT 2.0: Adjuvant T-DM1 vs THNCT04893109 · 2021-06-16 · 1 site observation

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 1 site observation

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesNCT03053193 · 2017-04-28 · 1 site observation

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · 2026-06-22 · 1 site observation

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · 2025-09-15 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · 2025-08-19 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · 2025-07-29 · 1 site observation

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · 2025-06-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · 2025-04-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 2025-04-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · 2025-04-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · 2025-04-22 · 1 site observation

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18 · 1 site observation

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.NCT06579105 · 2024-10-08 · 1 site observation

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090 · 2024-08-22 · 1 site observation

ACTIVE_NOT_RECRUITING

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874 · 2024-08-07 · 1 site observation

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487 · 2024-02-29 · 1 site observation

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.